These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19387202)

  • 1. Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.
    Jani AB; Fox TH; Whitaker D; Schuster DM
    Clin Nucl Med; 2009 May; 34(5):279-84. PubMed ID: 19387202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
    Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
    J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
    Nanni C; Schiavina R; Boschi S; Ambrosini V; Pettinato C; Brunocilla E; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S11-7. PubMed ID: 23591953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Rijkhorst EJ; Lakeman A; Nijkamp J; de Bois J; van Herk M; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1254-60. PubMed ID: 19857789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy.
    O'Daniel JC; Dong L; Zhang L; de Crevoisier R; Wang H; Lee AK; Cheung R; Tucker SL; Kudchadker RJ; Bonnen MD; Cox JD; Mohan R; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):883-91. PubMed ID: 17011461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.
    Oka S; Hattori R; Kurosaki F; Toyama M; Williams LA; Yu W; Votaw JR; Yoshida Y; Goodman MM; Ito O
    J Nucl Med; 2007 Jan; 48(1):46-55. PubMed ID: 17204698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
    Ren J; Yuan L; Wen G; Yang J
    Acta Radiol; 2016 Apr; 57(4):487-93. PubMed ID: 25907118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric effects of the prone and supine positions on image guided localized prostate cancer radiotherapy.
    Liu B; Lerma FA; Patel S; Amin P; Feng Y; Yi BY; Yu C
    Radiother Oncol; 2008 Jul; 88(1):67-76. PubMed ID: 18207595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
    Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
    Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of robustness of IMPT and IMRT for prostate cancer against organ movement.
    Soukup M; Söhn M; Yan D; Liang J; Alber M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):941-9. PubMed ID: 19801105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Ghilezan M; Yan D; Liang J; Jaffray D; Wong J; Martinez A
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1602-10. PubMed ID: 15590192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using
    Zamboglou C; Sachpazidis I; Koubar K; Drendel V; Wiehle R; Kirste S; Mix M; Schiller F; Mavroidis P; Meyer PT; Werner M; Grosu AL; Baltas D
    Radiother Oncol; 2017 Jun; 123(3):472-477. PubMed ID: 28499607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of image-guided patient repositioning and online planning in localized prostate cancer IMRT.
    Lerma FA; Liu B; Wang Z; Yi B; Amin P; Liu S; Feng Y; Yu CX
    Radiother Oncol; 2009 Oct; 93(1):18-24. PubMed ID: 19592122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dosimetric analysis comparing treatment of low-risk prostate cancer with TomoTherapy versus static field intensity modulated radiation therapy.
    Shah AP; Chen SS; Strauss JB; Kirk MC; Coleman JL; Coon AB; Miller C; Dickler A
    Am J Clin Oncol; 2009 Oct; 32(5):460-6. PubMed ID: 19564784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.